Print Friendly, PDF & Email

NCT/Study#

NCT04471844 /

EF-32

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma

DISEASE GROUP:

Neuro-Oncology

current phase:

NA

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587